Aligos Therapeutics, Inc. (ALGS)
6.95
-0.17
(-2.39%)
USD |
NASDAQ |
Feb 20, 10:19
Aligos Therapeutics EPS Diluted (Quarterly) : -3.041 for Sept. 30, 2025
EPS Diluted (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
EPS Diluted (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (Quarterly) Benchmarks
| Johnson & Johnson | 2.098 |
| ACADIA Pharmaceuticals, Inc. | 0.4206 |
| Agenus, Inc. | 1.944 |
| Alnylam Pharmaceuticals, Inc. | 1.368 |
| Savara, Inc. | -0.1366 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | -31.54M |
| Revenue (Quarterly) | 0.741M |
| Total Expenses (Quarterly) | 32.28M |
| Enterprise Value | -49.33M |
| Gross Profit Margin (Quarterly) | 70.31% |
| Profit Margin (Quarterly) | -4.26K% |
| Earnings Yield | -284.4% |
| Normalized Earnings Yield | -279.08 |